• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial.

作者信息

Shao Miner, Yao Jie, Wang Yunke, Zhao Lufeng, Li Baizhou, Li Lili, Wu Zuqun, Chen Zexin, Fan Junqiang, Qiu Fuming

机构信息

Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

出版信息

Signal Transduct Target Ther. 2023 Apr 10;8(1):146. doi: 10.1038/s41392-023-01355-1.

DOI:10.1038/s41392-023-01355-1
PMID:37032401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10083171/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afdb/10083171/a561aa28057b/41392_2023_1355_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afdb/10083171/a561aa28057b/41392_2023_1355_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afdb/10083171/a561aa28057b/41392_2023_1355_Fig1_HTML.jpg

相似文献

1
Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial.新辅助信迪利单抗联合化疗两周期与三周期用于可切除非小细胞肺癌：neoSCORE试验
Signal Transduct Target Ther. 2023 Apr 10;8(1):146. doi: 10.1038/s41392-023-01355-1.
2
NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer.NeoSCORE II：新辅助信迪利单抗+化疗治疗鳞状非小细胞肺癌的三个与四个周期。
Future Oncol. 2024 Jan;20(3):121-129. doi: 10.2217/fon-2024-0026. Epub 2024 Feb 14.
3
Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report.新辅助免疫联合化疗后 IIIA 期非小细胞肺癌患者原发肿瘤和纵隔淋巴结反应不同步：1 例报告。
Anticancer Drugs. 2022 Jan 1;33(1):e784-e788. doi: 10.1097/CAD.0000000000001204.
4
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.可切除的非鳞状非小细胞肺癌患者新辅助贝伐珠单抗联合化疗和辅助贝伐珠单抗的 II 期临床试验。
J Thorac Oncol. 2013 Aug;8(8):1084-90. doi: 10.1097/JTO.0b013e31829923ec.
5
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.在IIIA期非小细胞肺癌新辅助化疗中添加帕博利珠单抗后的完全病理缓解
J Oncol Pract. 2018 Sep;14(9):569-571. doi: 10.1200/JOP.18.00127. Epub 2018 Jul 25.
6
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
7
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.新辅助 PD-1 抑制剂（信迪利单抗）联合化疗（白蛋白紫杉醇联合卡铂）治疗可切除 IIIA/IIIB 期非小细胞肺癌的疗效和安全性的初步分析：一项单臂、Ⅱ期临床试验。
J Cancer Res Clin Oncol. 2023 Feb;149(2):819-831. doi: 10.1007/s00432-021-03896-w. Epub 2022 Feb 22.
8
Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer.可切除 IIIA 期非小细胞肺癌的新辅助信迪利单抗和化疗。
Ann Thorac Surg. 2022 Sep;114(3):949-958. doi: 10.1016/j.athoracsur.2022.01.039. Epub 2022 Feb 15.
9
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.新辅助化疗联合avelumab 治疗早期可切除非小细胞肺癌。
Cancer Med. 2020 Nov;9(22):8406-8411. doi: 10.1002/cam4.3456. Epub 2020 Sep 29.
10
[Controversy in the treatment of non-small cell lung cancer. Timing of chemotherapy in relation to surgery: before or after?].[非小细胞肺癌治疗中的争议。化疗与手术的时间关系：术前还是术后？]
Pneumologia. 2004 Jul-Sep;53(3):105-8.

引用本文的文献

1
Efficacy of adjuvant therapy regimens administered during the perioperative period in resectable non-small cell lung cancer.可切除非小细胞肺癌围手术期辅助治疗方案的疗效
Cancer Immunol Immunother. 2025 Sep 1;74(9):296. doi: 10.1007/s00262-025-04159-0.
2
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.CANOPY-N：一项关于卡那单抗或帕博利珠单抗单药或联合用药作为可切除的IB-IIIA期非小细胞肺癌患者新辅助治疗的2期研究。
JTO Clin Res Rep. 2025 Jun 13;6(8):100859. doi: 10.1016/j.jtocrr.2025.100859. eCollection 2025 Aug.
3

本文引用的文献

1
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
2
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌新辅助化疗联合纳武利尤单抗（NADIM）：一项开放标签、多中心、单臂、Ⅱ期临床试验。
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis.
可切除早期非小细胞肺癌新辅助、围手术期和辅助化疗免疫疗法的3期试验：全面综述与详细分析
JTO Clin Res Rep. 2025 Jun 19;6(9):100866. doi: 10.1016/j.jtocrr.2025.100866. eCollection 2025 Sep.
4
Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study.卡瑞利珠单抗在食管癌新辅助化疗中的分析：一项回顾性队列研究。
Oncol Lett. 2025 Jul 17;30(4):449. doi: 10.3892/ol.2025.15195. eCollection 2025 Oct.
5
Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.利用血清炎症指标预测可切除食管鳞状细胞癌对新辅助抗程序性死亡蛋白1联合化疗的病理反应
Sci Rep. 2025 Jul 31;15(1):27914. doi: 10.1038/s41598-025-11590-x.
6
[Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients
with Stage IB-IIIB Non-small Cell Lung Cancer].[IB-IIIB期非小细胞肺癌患者新辅助免疫化疗的疗效与安全性分析]
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):415-426. doi: 10.3779/j.issn.1009-3419.2025.106.16.
7
Influence of Cycles of Neoadjuvant Chemoimmunotherapy on Treatment Response in Stage IIIA-N2IIIB Non-small Cell Lung Cancer: Experience from a Large-Volume Center.新辅助化疗免疫治疗周期对IIIA-N2、IIIB期非小细胞肺癌治疗反应的影响：来自一个大容量中心的经验
Ann Surg Oncol. 2025 Jun 24. doi: 10.1245/s10434-025-17598-x.
8
Immunotherapy for resectable lung cancer.可切除肺癌的免疫疗法
Cancer. 2025 May 15;131(10):e35849. doi: 10.1002/cncr.35849.
9
Sleeve lobectomy versus lobectomy after neoadjuvant chemo-immunotherapy for non-small cell lung cancer invading the lobar bronchial orifice: a multicenter retrospective cohort study.新辅助化疗免疫治疗后，袖状肺叶切除术与肺叶切除术治疗侵犯叶支气管口的非小细胞肺癌：一项多中心回顾性队列研究
Transl Lung Cancer Res. 2025 Feb 28;14(2):408-421. doi: 10.21037/tlcr-24-925. Epub 2025 Feb 25.
10
Two versus three to four cycles of neoadjuvant immunochemotherapy for stage IB-IIIB non-small cell lung cancer: a real-world study.IB-IIIB期非小细胞肺癌新辅助免疫化疗两个周期与三至四个周期的比较：一项真实世界研究
J Thorac Dis. 2025 Feb 28;17(2):1028-1041. doi: 10.21037/jtd-2024-2256. Epub 2025 Feb 27.
Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24.
4
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
5
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.新辅助 PD-1 抑制剂（信迪利单抗）治疗 NSCLC。
J Thorac Oncol. 2020 May;15(5):816-826. doi: 10.1016/j.jtho.2020.01.017. Epub 2020 Feb 6.